GLP-1 (glucagon-like peptide-1) receptor agonists have emerged as one of the most significant breakthroughs in weight loss treatment in decades. Originally developed for type 2 diabetes management, these medications have shown remarkable effectiveness for sustainable weight loss.
How GLP-1 Medications Work
GLP-1 is a naturally occurring hormone in your body that plays several important roles:
GLP-1 receptor agonist medications mimic this natural hormone, amplifying its effects. The result? Reduced appetite, fewer cravings, and meaningful weight loss.
Clinical Results
Clinical trials have shown impressive results with GLP-1 medications:
Who Is a Good Candidate?
GLP-1 treatment may be appropriate if you:
Getting Started
The right first step is a conversation with a licensed physician who can review your history and tell you whether GLP-1 treatment fits your situation. If you want that input, you can take our 2-minute assessment.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Individual results may vary.
<!-- related-2026-injected -->
Related 2026 guides
Frequently Asked Questions
What is a GLP-1 medication?
A GLP-1 medication is a glucagon-like peptide-1 receptor agonist. It mimics a natural gut hormone that signals fullness to the brain, slows stomach emptying, and lowers blood sugar by increasing insulin release after meals. The first GLP-1 medications were approved for type 2 diabetes. More recent approvals (semaglutide as Wegovy in 2021 and tirzepatide as Zepbound in 2023) target chronic weight management directly. Tirzepatide also acts on the GIP receptor in addition to GLP-1, which is why it is classified as a dual agonist.
How do GLP-1 medications cause weight loss?
GLP-1 medications work through three mechanisms. First, they activate satiety signals in the hypothalamus so you feel full sooner and stay full longer. Second, they slow gastric emptying so food remains in the stomach longer, reducing the urge to eat between meals. Third, they reduce reward-driven eating by acting on dopamine pathways tied to food cravings. The result is that most patients eat less without consciously trying to. In the STEP-1 trial (NEJM 2021), adults on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks. In SURMOUNT-1 (NEJM 2022), adults on tirzepatide 15 mg lost an average of 20.9% at 72 weeks.
Which GLP-1 medications are FDA-approved in 2026?
Eight brand-name GLP-1 medications hold FDA approval in 2026: Ozempic, Wegovy, Rybelsus (all semaglutide, Novo Nordisk); Mounjaro, Zepbound (both tirzepatide, Eli Lilly); Saxenda, Victoza (both liraglutide); and Trulicity (dulaglutide). Wegovy and Zepbound are the two specifically approved for chronic weight management. The others are FDA-approved for type 2 diabetes and may be prescribed off-label for weight loss at physician discretion. Compounded versions of semaglutide and tirzepatide are also available through state-licensed compounding pharmacies, but compounded medications are not FDA-approved as final products.
Who is a candidate for GLP-1 weight loss medication?
Standard FDA labeling for weight-management GLP-1s targets adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. A US-licensed physician evaluates your medical history, current medications, and contraindications to confirm eligibility. Common contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, prior pancreatitis, severe gastroparesis, and pregnancy or planned pregnancy in the near term.
How quickly do GLP-1 medications start working?
Appetite suppression often begins within the first 1 to 2 weeks of treatment. Visible weight reduction typically starts in the first month and accelerates between months 3 and 6 as the dose escalates. Peak weight reduction in clinical trials occurred between months 6 and 9 of consistent treatment, which is why long-term adherence matters more than initial response. Patients who stop in month 3 or 4 often miss the largest portion of their potential weight loss.
Majesta Health medical content is written against primary sources (FDA labels, peer-reviewed trials, HHS and CDC publications) and passes a documented compliance review before publication. We are rolling out named physician review with US-licensed clinicians from our partner MD Integrations (MDI): each reviewed article will show the reviewing physician's name, NPI, and review date. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across the states we currently serve through the MD Integrations Medical Services Organization (coverage varies by state; see our states page)
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited); Majesta prescriptions are dispensed through Belmar's state-licensed 503A compounding pharmacy